GlassScriptPhysician profile
Harshavardhan L Dalal
NPI 1700812823
$49,743.01
in general payments reported to CMS, 2019-2025
43 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $5,125 · 2021: $3,415 · 2022: $6,840 · 2023: $2,729 · 2024: $2,270 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,475.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,828.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,096.32 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Allergan, INC. | $6,931.48 | 2019-2020 | |
| Abbvie INC. | $6,613.50 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Ironwood Pharmaceuticals, INC | $2,743.53 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $1,145.76 | 2021-2023 | |
| Janssen Biotech, INC. | $1,052.92 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,016.37 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $374.24 | 2019-2024 | |
| Qol Medical, LLC | $353.89 | 2019-2025 | Sucraid |
| Genzyme Corporation | $316.14 | 2023-2025 | |
| Boston Scientific Corporation | $303.98 | 2022-2024 | Watchman Flx |
| Celgene Corporation | $297.47 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $290.59 | 2020-2023 | Stelara |
| Merck Sharp & Dohme LLC | $286.49 | 2019-2023 | Dificid, Zinplava |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshavardhan Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.